IN8bio Consensus Price Target Raised 12% to $7.14
The average one-year price target for IN8bio (NASDAQCM:INAB) (DB:6JH0) has been revised to $7.14 / share. This is an increase of 12.00% from the prior estimate of $6.38 dated September 11, 2026. These figures represent aggregate analyst targets compiled from multiple sources and do not constitute a recommendation orinvestment adviceby Fintel.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $5.05 to a high of $10.50 / share. The average price target represents an increase of 417.39% from the latest reported closing price of $1.38 / share, recorded on October 2, 2026. The current median target increased to $6.12 from a prior median of $5.61, representing an absolute median change of $0.51. The target range narrowed, with the current target range width at $5.45 compared to a prior width of $6.46, which is a target range width change percent of -15.63%. The absolute mean target change is $0.76, and the current mean-median gap stands at $1.02.
Looking at the target history, the mean target was $7.14 on October 3, 2026, after holding at $6.38 on September 15, 2026, August 28, 2026, and August 4, 2026. This represents a target change since the 90-day baseline of +12.00% from the baseline date of June 30, 2026. Among the observed twelve-month mean targets, the observed twelve-month high mean was $50.74 on February 26, 2026, and the observed twelve-month low mean was $6.38 on September 15, 2026.
As context, the stock has experienced recent price movements. The price change over one week was +15.00% from a baseline close of $1.20 on September 25, 2026. Over one month, the price change was +25.45% from a baseline close of $1.10 on September 2, 2026. In its latest earnings report on August 6, 2026, IN8bio reported an actual EPS of -0.25, compared to an estimated EPS of -0.3808. Both actual and estimated revenues were reported at $0.00.
Analyst sentiment has remained steady. For the current recommendation period of September 1, 2026, there are 2 strong buy, 7 buy, and 1 hold recommendations, totaling 10 recommendations. This represents 90.0% positive recommendations and 10.0% hold recommendations, which is unchanged from the prior recommendation period of August 1, 2026. Within the broader Biotechnology sub-industry, 24 companies are covered. Among these, 7 companies had their targets raised, 6 were lowered, and 11 remained unchanged. The sub-industry median revision percent is 0.00%, and the sub-industry median implied change percent is +79.31%.
IN8bio, Inc. is a biotechnology firm based in the United States, primarily focused on the development of cancer therapeutics. The company specializes in the innovation of novel treatments using gamma-delta T cells, a type of immune cell with potential anti-cancer properties. A key project of IN8bio is its research and development of "Drug Resistant Immunotherapy" (DRI), designed to enhance the efficacy and safety of cancer treatments that involve chemotherapy alongside cell therapies. Their work also extends to exploring the potential of these treatments in various cancer types, including acute leukemia and solid tumors.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.